XTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Key Points

• XTX Topco Ltd acquired a $282,000 stake in Taysha Gene Therapies, purchasing 203,129 shares, which represents approximately 0.10% ownership of the company.
• Wall Street analysts are optimistic about Taysha Gene Therapies, with average ratings of "Buy" and a consensus price target of $8.17.
• Major shareholder Paul B. Manning increased his holdings by purchasing 750,000 shares at an average price of $2.75, bringing his total ownership to 2,841,704 shares.

XTX Topco Ltd acquired a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 203,129 shares of the company's stock, valued at approximately $282,000. XTX Topco Ltd owned about 0.10% of Taysha Gene Therapies at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Ground Swell Capital LLC purchased a new position in Taysha Gene Therapies during the fourth quarter worth about $25,000. Hsbc Holdings PLC raised its position in Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after acquiring an additional 8,076 shares during the period. Ameriprise Financial Inc. bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $40,000. BNP Paribas Financial Markets bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $41,000. Finally, First Manhattan CO. LLC. bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $49,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TSHA has been the topic of several research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Bank of America initiated coverage on shares of Taysha Gene Therapies in a research report on Friday, July 11th. They issued a "buy" rating and a $8.00 price objective on the stock. Canaccord Genuity Group lifted their price objective on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, June 3rd. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Finally, JMP Securities boosted their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research report on Thursday, May 29th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and a consensus price target of $8.17.

Insiders Place Their Bets

In related news, major shareholder Paul B. Manning purchased 750,000 shares of the firm's stock in a transaction dated Friday, May 30th. The shares were purchased at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the acquisition, the insider directly owned 2,841,704 shares of the company's stock, valued at approximately $7,814,686. This represents a 35.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.78% of the company's stock.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $2.76 on Tuesday. The firm's 50 day simple moving average is $2.59 and its 200 day simple moving average is $2.08. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $592.46 million, a PE ratio of -8.12 and a beta of 0.98. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $3.31.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative return on equity of 104.93%. During the same quarter in the prior year, the firm posted ($0.10) EPS. As a group, analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.